ATE857T1 - Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine. - Google Patents

Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine.

Info

Publication number
ATE857T1
ATE857T1 AT79104391T AT79104391T ATE857T1 AT E857 T1 ATE857 T1 AT E857T1 AT 79104391 T AT79104391 T AT 79104391T AT 79104391 T AT79104391 T AT 79104391T AT E857 T1 ATE857 T1 AT E857T1
Authority
AT
Austria
Prior art keywords
membrane proteins
neisseria meningitidis
production
vaccine containing
optionally
Prior art date
Application number
AT79104391T
Other languages
English (en)
Inventor
Torsten Bertil Dr. Helting
Gerhard Dr. Guthoehrlein
Original Assignee
Behringwerke Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Aktiengesellschaft filed Critical Behringwerke Aktiengesellschaft
Application granted granted Critical
Publication of ATE857T1 publication Critical patent/ATE857T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT79104391T 1978-11-11 1979-11-08 Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine. ATE857T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19782848965 DE2848965A1 (de) 1978-11-11 1978-11-11 Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
EP79104391A EP0011243B1 (de) 1978-11-11 1979-11-08 Verfahren zur Herstellung von Membranproteinen aus Neisseria meningitidis und diese enthaltende Vaccine

Publications (1)

Publication Number Publication Date
ATE857T1 true ATE857T1 (de) 1982-04-15

Family

ID=6054405

Family Applications (1)

Application Number Title Priority Date Filing Date
AT79104391T ATE857T1 (de) 1978-11-11 1979-11-08 Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine.

Country Status (9)

Country Link
EP (1) EP0011243B1 (de)
JP (1) JPS5566519A (de)
AT (1) ATE857T1 (de)
AU (1) AU533386B2 (de)
CA (1) CA1142083A (de)
DE (2) DE2848965A1 (de)
DK (1) DK154841C (de)
ES (1) ES485715A1 (de)
IL (1) IL58673A (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4317811A (en) 1980-09-11 1982-03-02 Merck & Co., Inc. Herpes simplex type 1 subunit vaccine
EP0127681B1 (de) * 1982-12-02 1993-03-03 The Rockefeller University Ig-A BINDENDES PROTEIN
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
JP5074644B2 (ja) 1998-05-29 2012-11-14 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド 組合わせの髄膜炎菌b/cワクチン
AU783894B2 (en) 1999-05-19 2005-12-22 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
GB0103171D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
CA2493124C (en) 2002-08-02 2014-04-29 Glaxosmithkline Biologicals S.A. Vaccine
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CU23313A1 (es) 2002-11-27 2008-09-25 Inst Finlay Ct De Investigacia Mã0/00todo de obtenciã"n de estructuras cocleares. composiciones vacunales y adyuvantes basados en estructuras cocleares y sus intermediarios
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
JP5173194B2 (ja) * 2003-12-23 2013-03-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
DE602007003596D1 (de) 2006-06-12 2010-01-14 Glaxosmithkline Biolog Sa Impfstoff
BR122016015627A2 (pt) 2007-10-19 2018-10-30 Novartis Ag kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
EP2886551A3 (de) 2008-02-21 2015-09-23 Novartis AG Meningokokken-FHBP-Polypeptide
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
WO2010070453A2 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
JP2013502918A (ja) 2009-08-27 2013-01-31 ノバルティス アーゲー 髄膜炎菌fHBP配列を含むハイブリッドポリペプチド
US8858958B2 (en) 2009-08-27 2014-10-14 Novartis Ag Adjuvant comprising aluminum, oligonucleotide and polycation
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
US20130022639A1 (en) 2009-09-30 2013-01-24 Novartis Ag Expression of meningococcal fhbp polypeptides
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
US9408907B2 (en) 2009-12-15 2016-08-09 Glaxosmithkline Biologicals Sa Homogenous suspension of immunopotentiating compounds and uses thereof
EP2544714A1 (de) 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Impfstoffzusammensetzung
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
BR112013005626B1 (pt) 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
MX2014008988A (es) 2012-02-02 2014-08-27 Novartis Ag Promotores para aumento de expresion de proteinas en meningococo.
ES2750366T3 (es) 2012-03-08 2020-03-25 Glaxosmithkline Biologicals Sa Ensayo de potencia in vitro para vacunas meningocócicas basadas en proteína
MX357538B (es) 2012-06-14 2018-07-13 Novartis Ag Vacunas para meningococo de serogrupo x.
EP2892553A1 (de) 2012-09-06 2015-07-15 Novartis AG Kombinationsvakzine mit serogruppe-b-meningokokken und d/t/p
RU2662970C2 (ru) 2012-09-18 2018-07-31 Новартис Аг Везикулы наружной мембраны
CA2940447C (en) 2014-02-28 2023-07-11 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
WO2018042015A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
CN111148531A (zh) 2017-09-08 2020-05-12 伊夫罗生物科学公司 细菌胞外囊泡
EP3607967A1 (de) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modifizierte meningokokken fhbp polypeptide
US12128094B2 (en) 2018-11-06 2024-10-29 Glaxosmithkline Biologicals Sa Immunogenic compositions comprising OMVs, an acellular pertussis antigen, a tetanus toxoid and a diphtheria toxoid
EP3799884A1 (de) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogene zusammensetzungen
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202115072D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process

Also Published As

Publication number Publication date
DK154841C (da) 1989-06-05
EP0011243B1 (de) 1982-04-14
JPS5566519A (en) 1980-05-20
AU5268279A (en) 1980-05-15
CA1142083A (en) 1983-03-01
IL58673A0 (en) 1980-02-29
EP0011243A1 (de) 1980-05-28
DK154841B (da) 1988-12-27
DE2848965A1 (de) 1980-05-22
ES485715A1 (es) 1980-05-16
AU533386B2 (en) 1983-11-24
IL58673A (en) 1983-02-23
DE2962526D1 (en) 1982-05-27
JPS6350332B2 (de) 1988-10-07
DK475779A (da) 1980-05-12

Similar Documents

Publication Publication Date Title
JPS5566519A (en) Manufacture of membrane protein and vaccine containing it
ATE195420T1 (de) Methode zur herstellung von eicosapentansäuren
DE3767077D1 (de) Verfahren zur abtrennung von cholesterin aus fettsubstanzen tierischen ursprungs und cholesterinarme fettsubstanzen.
DE68906385D1 (de) Verfahren und vorrichtung zur reinigung von wasser mittels polypyrrolidon.
DE3688340D1 (de) Milchsaeurehaltige fruchtprodukte und verfahren zur lactofermentation von fruchtprodukten.
ATE944T1 (de) Verfahren zur herstellung von knochenersatzmaterial mit verbesserter biologischer stabilitaet auf der basis von kollagen und das erhaltene knochenersatzmaterial.
DE60107446D1 (de) Gereinigtes cochinealpigment und verfahren zur herstellung desselben
ATE42965T1 (de) Verfahren zur herstellung von stabilen ozonisierten oelen aus ungesaettigten pflanzenoelen.
AT384032B (de) Verfahren zur herstellung von polydispersen nativen pseudomonas-flagella(h)-antigenen (fag)
DE69105782D1 (de) Verfahren zur Herstellung von Wäscheweichspülmitteln mit hohem Feststoffgehalt benutzend geringen Lösungsmittelgehalt und beseitigend Nebenreaktionen.
ATE70452T1 (de) Verfahren zur herstellung eines propolis|thanolextraktes.
DE3585416D1 (de) Verfahren zur herstellung eines biologischen stoffes.
DE69032153D1 (de) Verfahren zur Herstellung von Butantetracarboxylat
DE59209053D1 (de) Verfahren zur Herstellung aktivierter Sialinsäuren
ATE196088T1 (de) Verfahren zur gewinnnung von zellkulturen mit erhöhtem gehalt an körpereigenen zytokinen
ATE30161T1 (de) Verfahren zur herstellung von globin aus haemoglobin und das in diesem verfahren erhaltene globin.
DE3265664D1 (en) Process for the production of a biochemical vaccine against salmonella fevers
ATE100148T1 (de) Verfahren zur herstellung von hochgradig ungesaettigten fettsaeuren.
ATE92056T1 (de) Verfahren zur herstellung von 5-chlor-3chlorsulfonyl-2-thiophencarbonsaeureestern.
FR2620726B1 (fr) Procede de preparation d'un extrait de jasmin et extrait obtenu
ATE116989T1 (de) Verfahren zur reinigung von hemin, neues heminderivat und verfahren zur herstellung.
ATE14596T1 (de) Verfahren zur herstellung von ammoniumlactat enthaltenden mischungen und vorrichtung zur durchfuehrung des verfahrens.
FR2429765A1 (fr) Procede et agent d'adsorption pour isoler des enzymes et pour les preparer a l'etat pur
ATE101393T1 (de) Phenanthridinderivate, verfahren zu ihrer herstellung und mittel zur ausfuehrung des verfahrens.
DE59106227D1 (de) Verfahren zur herstellung von spagyrischen essenzen aus pflanzen.

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time